<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757287</url>
  </required_header>
  <id_info>
    <org_study_id>SMD-DES-2016-01</org_study_id>
    <nct_id>NCT02757287</nct_id>
  </id_info>
  <brief_title>Desogestrel (DSG) and Corifollitropin(FSH-CTP) Alfa for Ovarian Stimulation in Donors</brief_title>
  <official_title>Desogestrel and Corifollitropin Treatment for Ovarian Stimulation in Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Universitari Dexeus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Dexeus Salud de la Mujer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Universitari Dexeus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, controlled ovarian stimulation (COS) in oocyte donors is performed by daily&#xD;
      injections of gonadotropins( recombinant FSH) plus a GnRH Antagonist usually form 5th-6th&#xD;
      stimulation day until ovulation induction with a bolus of another injection of a&#xD;
      gonadotropin-releasing hormone (GnRH) Agonist. Injections of the GnRH Antagonist avoid&#xD;
      untimely luteinizing hormone (LH) surge and spontaneous ovulation prior to follicular&#xD;
      aspiration. There is a preparation of long-acting recombinant follicle stimulating hormone&#xD;
      (rFSH= (corifollitropin alfa (FSH-CTP), Elonva®, MSD), that allows that a single subcutaneous&#xD;
      injection substitutes the first 7 days of daily gonadotropin injections. On the other hand, a&#xD;
      contraceptive oral progesterone only( Desogestrel, DSG) is available for contraception,&#xD;
      avoiding the LH surge. It has been described the usefulness of orally administered&#xD;
      medroxyprogesterone acetate, 10 mg to inhibit the endogenous LH surge in IVF patients during&#xD;
      COS.&#xD;
&#xD;
      In donors, by administering a single injection of FSH-CTP and oral desogestrel since the&#xD;
      first menstruation day, the total number of injections administered is reduced and less&#xD;
      discomfort is experienced without adverse impact on ovarian response. No description of the&#xD;
      hormonal and ovarian response under this protocol has been published&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  oral desogestrel since the first menstruation day,&#xD;
&#xD;
        -  a single injection of FSH-CTP on the 7th menstrual cycle day&#xD;
&#xD;
        -  routine monitoring of ovarian response with transvaginal ultrasound every second day&#xD;
           until pre-ovulatory bolus of GnRH&#xD;
&#xD;
        -  Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH&#xD;
           and the day after the bolus ( estradiol, FSH, Progesterone, LH)&#xD;
&#xD;
        -  Quality of Life questionnaire the day after the bolus&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of financial support&#xD;
  </why_stopped>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total dose of gonadotrophins</measure>
    <time_frame>At the end of the stimulation treatment period (5 or 7 days after begining of treatment)</time_frame>
    <description>Total Consume of gonadotrophins</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma LH</measure>
    <time_frame>Day of GnrH bolus</time_frame>
    <description>Level of LH in plasma (mIU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of mature oocytes</measure>
    <time_frame>Day of oocyte recovery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>FSH-CTP + DESOGESTREL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of FSH-CTP and oral desogestrel since the first menstruation day, until bolus of GnRH agonist to follicular maturation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FSH-CTP + DESOGESTREL</intervention_name>
    <description>Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)&#xD;
- Quality of Life questionnaire the day after the bolus</description>
    <arm_group_label>FSH-CTP + DESOGESTREL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Population: donors (18-35 ) from candidates of Donor program&#xD;
&#xD;
          -  Fulfilling inclusión medical and legal criteria (RD -Ley de transposición de la&#xD;
             normativa europea a la legislación española 9/2014)&#xD;
&#xD;
          -  Who had had undergone previously convencional COS (controlled ovarian stimulation)&#xD;
             with FSH-CTP and daily antagonist injections&#xD;
&#xD;
          -  Given signed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous low response to COS&#xD;
&#xD;
          -  Previous ovarian hyperstimulation syndrome.&#xD;
&#xD;
          -  Ovarian cysts.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Quiron Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.dexeus.com/</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Martínez F, Boada M, Coroleu B, Clua E, Parera N, Rodríguez I, Barri PN. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH. Hum Reprod. 2006 Aug;21(8):2121-5. Epub 2006 Apr 21.</citation>
    <PMID>16632462</PMID>
  </reference>
  <reference>
    <citation>Martínez F, Clua E, Santmartí P, Boada M, Rodriguez I, Coroleu B. Randomized, comparative pilot study of pituitary suppression with depot leuprorelin versus cetrorelix acetate 3 mg in gonadotropin stimulation protocols for oocyte donors. Fertil Steril. 2010 Nov;94(6):2433-6. doi: 10.1016/j.fertnstert.2010.02.059. Epub 2010 Apr 28.</citation>
    <PMID>20430379</PMID>
  </reference>
  <reference>
    <citation>Requena A, Cruz M, Collado D, Izquierdo A, Ballesteros A, Muñoz M, García-Velasco JA. Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin α. Reprod Biomed Online. 2013 Mar;26(3):253-9. doi: 10.1016/j.rbmo.2012.11.015. Epub 2012 Dec 5.</citation>
    <PMID>23352098</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>September 3, 2018</last_update_submitted>
  <last_update_submitted_qc>September 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Universitari Dexeus</investigator_affiliation>
    <investigator_full_name>Dr. Francisca Martínez</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Ovarian stimulation</keyword>
  <keyword>LH inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

